Pandemic could give advantage to newly approved MS latecomer ofatumumab

With FDA’s approval of Kesimpta ofatumumab for multiple sclerosis, Novartis could become the latest company to reap the added benefits of launching a drug with a convenient route of administration during the pandemic. 

FDA approved the once-monthly, auto-injectable anti-CD20 mAb to treat relapsing forms of MS on Thursday after a three-month delay in the agency’s review. An IV version of the drug has been marketed as Arzerra for chronic lymphocytic leukemia (CLL) for more than a decade ago...